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AtriAl fibrillation has long been shown to increase the risk of stroke and death.5,6 Pharmacological stroke prevention agents for nonvalvular atrial 
fibrillation have evolved in an effort to address various 
aspects of the coagulation cascade. Specific efforts aimed 
at altering thrombus formation have included platelet 
function inhibitors, such as aspirin and clopidogrel, and 
vitamin K blockade, with warfarin. Treatment with war-
farin results in a relative stroke risk reduction of 60%;6 
however, this drug’s efficacy has been hindered by the 
need for frequent monitoring, multiple interactions with 
food and other medications, and its increased risk of hem-
orrhage.1 Newer agents have aimed at more direct coagu-
lation factor inhibition. Large, randomized, multicenter 
noninferiority trials have shown that direct thrombin in-
hibitors, such as dabigatran, have lower rates of stroke 
and systemic embolism than warfarin with decreased 
rates of major hemorrhage.1,3 In the event of traumatic 
hemorrhage in patients receiving dabigatran, however, 
there are currently no effective reversal agents. Familiar-
ity with this new anticoagulation agent is critical in the 
neurosurgical community so that management options, 
while currently limited, can be implemented in a timely 
fashion.
Case Report
This 83-year-old man was evaluated in the emer-
gency department after a ground-level fall at home. One 
month earlier, he had been diagnosed with new-onset 
atrial fibrillation and started on dabigatran 150 mg twice 
a day by his primary care physician. On initial neurosur-
gical evaluation, the patient was found to have a GCS of 
15.9 Noncontrast CT revealed a right temporal intraparen-
chymal hemorrhage with surrounding cerebral edema, as 
well as a small right subdural hematoma and a small area 
of SAH (Fig. 1 left). There was also a small amount of left 
frontal lobe and left parietal lobe SAH (Fig. 1 right). Ini-
tial laboratory values revealed an international normal-
ized ratio of 1.4, a prothrombin time of 17.2 seconds (nor-
mal range 12–15.5 seconds), and a partial thromboplastin 
time of 43 seconds (normal range 24–35 seconds). Platelet 
counts were normal at 271. The thrombin time was also 
measured and found to exceed 150 seconds (normal range 
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14.7–19.5 seconds). The patient was admitted to the neu-
rocritical care unit for serial neurological examinations.
Approximately 2 hours after admission to the inten-
sive care unit, the patient developed dysarthric speech, 
although he was still able to briskly follow commands. 
Repeat CT demonstrated significant interval progression 
of both the right parenchymal and left frontal hemor-
rhages (Fig. 2A). Although the neurosurgical team was 
aware of the limited options available for reversal of dab-
igatran, a weight-based dose of recombinant factor VII 
was administered because it has a rapid onset of action. 
The patient’s mental status continued to decline, however, 
and he required emergency endotracheal intubation for 
a GCS score of 6 (E1, V1, M4).9 A final CT scan, ob-
tained only 6 hours after his initial presentation, showed 
extensive progression of the patient’s bilateral intrapa-
renchymal hemorrhages, now encompassing most of the 
left hemisphere with 7 mm of left-to-right midline shift 
and effacement of the left lateral ventricle (Fig. 2B). After 
extensive discussion with the patient’s family regarding 
his poor neurological prognosis, the decision was made 
to transition the patient to comfort care. The patient died 
shortly thereafter.
Discussion
The recent approval of dabigatran by the US FDA 
for stroke and systemic embolism prevention in patients 
with atrial fibrillation presents a new dilemma for neu-
rosurgeons. Patients treated with dabigatran are often el-
derly individuals with multiple comorbidities. Imbalance 
and falls are common in this population, and intracranial 
hemorrhage resulting even from minor trauma may occur 
with increasing frequency as use of this drug becomes 
more widespread.
Atrial fibrillation is characterized by a loss of or-
ganized atrial contraction, which can lead to stasis and 
thrombus formation. In patients with nonvalvular atrial 
fibrillation, the annual risk of stroke can be calculated ac-
cording to the CHADS2 criteria.7 Because thrombin plays 
a key role in fibrin clot formation and is essential to blood 
coagulation, it is an attractive target for pharmaceutical 
agents. Current anticoagulants such as unfractionated 
low-molecular-weight heparin and the vitamin K antago-
nist warfarin require frequent blood draws and dosing ad-
justments to ensure patients remain in a therapeutic range.
Dabigatran is a synthetic thrombin inhibitor that 
binds directly to clot-bound and free thrombin with high 
specificity.8 Pharmacokinetic highlights include 80% re-
nal excretion and a serum half-life of 12–17 hours. Be-
cause of its half-life, which is shorter than that of war-
farin, dabigatran is typically administered twice daily. It 
is not metabolized by cytochrome p450 isoenzymes and 
therefore is less likely to potentiate drug-drug interac-
tions.8 In addition, because dabigatran has been shown 
to have little interaction with food or drugs, it can be pre-
scribed in a fixed dose without the constraints of frequent 
monitoring.8 The most common side effect of dabigatran 
is dyspepsia, although clinical trial results indicate a pos-
sible increased risk of myocardial infarction in patients 
taking this drug.1 The mechanism behind this cardiac 
dysfunction is currently unknown.
Analysis by the RE-LY (Randomized Evaluation of 
Long Term Anticoagulant Therapy) trial investigators3 
showed that lower doses of dabigatran (110 mg twice 
daily) had a lower rate of intracranial hemorrhage when 
compared with warfarin, while a higher dose (150 mg 
twice daily) had a similar rate. Additionally, the higher-
dose dabigatran was superior to warfarin in the annual 
rate of stroke and systemic embolism. Postulated to by-
Fig. 1. Noncontrast head CT scans obtained in the emergency department showing right temporal intraparenchymal hemor-
rhage with associated subdural hemorrhage and SAH (left) and left frontal subarachnoid blood (right).
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pass the activated factor VII–tissue factor binding that 
is integral to initiating coagulation, dabigatran preserves 
hemostatic protection mechanisms that the brain employs 
to limit spontaneous intracranial hemorrhage.3 In addi-
tion to its use in stroke and systemic embolism preven-
tion in patients with atrial fibrillation, dabigatran is also 
currently approved in both Europe and Canada for the 
prevention and treatment of venous thromboembolism.8
There is currently no effective antidote to reverse the 
anticoagulant effect of dabigatran in the event of an emer-
gency. As a direct thrombin (factor II) inhibitor, dabiga-
tran exerts its mechanism of action at the very end of the 
coagulation cascade, and therefore both factor VIIa and 
fresh-frozen plasma are ineffective as treatment options. 
One recent randomized clinical trial showed no effect of 
prothrombin complex concentrate on the anticoagulant 
effect of dabigatran.2 Although recent preclinical trials 
using murine models have shown that high-dose pro-
thrombin complex concentrate slows the expansion of 
intracerebral hematoma, direct clinical applicability is 
limited by a lack of neurological outcome monitoring and 
appropriate safety and efficacy studies.10 Additionally, 
prothrombin complex concentrate is not currently avail-
able at our institution and so was not used in this case. 
Because dabigatran is primarily renally excreted, dialysis 
is an alternative for drug clearance and can remove ap-
proximately 35%–60% of the drug in 2–3 hours.4 Dialy-
sis was not considered at the time of initial presentation 
of our patient, and by the time of his deterioration it was 
too late to implement effectively.
While dabigatran can alter the activated prothrombin 
time, this has not been shown to be an effective measure 
of systemic anticoagulation. The thrombin time is the 
most sensitive laboratory test to assess the effects of dabi-
gatran in urgent clinical situations. In addition, the throm-
bin time is a rapidly obtained laboratory value that should 
be readily available in the inpatient and emergency de-
partment setting. Our patient presented with a markedly 
elevated thrombin time, which could have been serially 
monitored to assess his response to dabigatran had his 
clinical course been prolonged.
As stated, recombinant factor VII administration 
failed to slow the progression of our patient’s intracra-
nial hemorrhage. Dabigatran is different from warfarin, 
whose inhibitory effect on clotting factors II, VII, IX, and 
X can be reversed by fresh-frozen plasma, vitamin K, and 
factor VII. In the absence of an effective antidote, treating 
physicians should consider obtaining a thrombin time and 
instituting early use of dialysis in conjunction with judi-
cious use of intravenous fluid administration to maintain 
renal perfusion. Caution is necessary, however, because 
patients with atrial fibrillation have tenuous intravascular 
volume status, and fluid overload can lead to worsening 
heart function. Dabigatran is only the first of several di-
rect thrombin inhibitors that may enter clinical use (Table 
1), and these agents will likely have similar risks for cata-
strophic progression of traumatic injuries.
Conclusions
New direct coagulation factor inhibitors, such as dab-
igatran, have demonstrated superior stroke and systemic 
embolism prevention without the burdensome monitor-
ing and drug-drug interactions seen with agents such as 
warfarin. Although dabigatran has been shown to have 
a lower incidence of major bleeding than warfarin, in 
the event of catastrophic hemorrhage no effective rever-
sal agent exists. Neurosurgeons are likely to encounter 
this clinical scenario more frequently with the increased 
use of dabigatran and other similar drugs. Preclinical 
and early clinical trials have thus far failed to yield an 
effective reversal agent for these medications, and new 
treatments are certainly needed. The authors stress that 
a high index of suspicion for catastrophic hemorrhage is 
Fig. 2. Noncontrast head CT scans. A: Study obtained approximately 2.5 hours postadmission showing significant interval 
evolution of the patient’s intracranial hemorrhage bilaterally. B: Study obtained 6 hours postadmission revealing significant 
further progression of the patient’s intracranial hemorrhage.
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required in patients taking dabigatran so that the limited 
management options can be evaluated and implemented 
without potentially life-threatening delay.
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TABLE 1: List of direct thrombin inhibitors*
Drug Name Brand Name FDA Regulatory Status
dabigatran 
 etexilate
Pradaxa approved for prevention of stroke & blood 
 clots in patients w/ nonvalvular atrial 
  fibrillation (2010)
Argatroban Argatroban approved for prophylaxis or treatment of 
  thrombosis in patients w/ HIT (2000) & 
 for use during PCI in patients w/ or at 
  risk for HIT (2002) 
lepirudin Refludan approved for the treatment of HIT Type II 
  (1998)
bivalirudin Angiomax approved for use w/ aspirin & provisional 
 glycoprotein inhibitors as anticoagula- 
 tion therapy for patients undergoing a 
  PCI (2005)
desirudin Iprivask approved for the prevention of DVT in pa- 
 tients undergoing elective hip replace- 
  ment (2003); tested in randomized trial 
 in patients w/ HIT 
AZD0837 tested in a randomized Phase II study for 
  patients w/ atrial fibrillation; compared 
 w/ vitamin K antagonists in nonran- 
  domized Phase II study in patients w/ 
  nonvalvular atrial fibrillation
M118 tested in Phase II study for use as antico- 
 agulant in patients w/ stable coronary 
 artery disease undergoing a PCI
*  DVT = deep venous thrombosis; HIT = heparin-induced thrombocyto-
penia; PCI = percutaneous coronary intervention.
